An opportunity to participate in future cancer research studies


The Exactis Personalize My Treatment (PMT) program is a pan-Canadian oncology initiative in which participants consent to provide blood, tissue samples and clinical data for cancer research.


As a cancer patient, your tumour tissue, blood samples and clinical data contain valuable information that may help advance cancer research. Each cancer has unique molecular properties, also called a “molecular profile.”


Determining the molecular profile of your tumour could accelerate the development of new treatments targeting tumours with specific molecular profiles.


The main goals of PMT are to:
  • Facilitate and accelerate the development of better diagnostic and screening tests, and better treatments for cancer patients

  • Support cancer research by building a large collection of cancer samples and data to which researchers will be able to request access

  • Match patients to available clinical trials specific to the molecular profile of their tumour and/or type of cancer


What are the benefits?

Participating in PMT offers no direct benefit to you. Your participation will contribute to the advancement of cancer research.


What are the risks?

Participating in PMT poses no additional physical risks, since no procedures are done solely for PMT.


If samples are collected for PMT during a routine procedure (such as a biopsy or a blood draw), this will add a few minutes to the procedure. The risks are the same as associated with the routine procedure.


As in any research project, there is a small risk of participant identification. Exactis takes measures to minimize this risk.


Patients participating in the PMT initiative, consent to: 
  • ​Provide tumour tissue or other biospecimens for molecular profiling 

  • Share their coded molecular and clinical data

  • Be contacted for clinical trials or other research

  • Be followed through their disease trajectory


What am I consenting to?

If you choose to participate in PMT, you consent to:

  • Provide blood or tissue samples collected during standard of care procedures

  • Allow access to relevant clinical and molecular information such as your cancer type and treatment history

  • Be contacted for possible participation in a clinical trial or to provide additional information or samples


Can I withdraw my consent?

Participation in PMT is completely voluntary. You can withdraw from PMT at any time by informing the Principal Investigator at your hospital. You are not required to give any reasons. Withdrawing from PMT will have no effect on your current or future care.


How is my privacy protected?

Precautions are taken to protect your privacy and confidentiality:

  • Your personal identifying information will only be available to authorized personnel

  • within your hospital

  • Your personal identifying information will be replaced by a code before your data and

  • samples are stored in the PMT Platform or shared with researchers

  • No evidence of participation in PMT will appear in your medical record

I am a cancer patient. How can I sign up for PMT?

Cancer patients at hospitals where PMT is active can ask their oncologist about participating in PMT (see list of active locations below). Your oncologist can see if you would be a candidate for PMT and can tell you more about what your participation would involve. Exactis Innovation cannot offer advice on how to treat your cancer –  speak to your oncologist about your best treatment options. Sample profiling and clinical trial matching is not guaranteed for all patients.




Tom Baker Cancer Centre

Calgary, Alberta, Canada

T2N 4N2 

Contact: Tracy Xu   

Principal Investigator: Gwyn Bebb, MD


New Brunswick

Centre hospitalier universitaire Dr-Georges-L.-Dumont

Moncton, New Brunswick, Canada

E1C 2Z3 

Contact: Stéphanie Crapoulet 506-862-4221       

Principal Investigator: Eve St-Hilaire, MD


The Moncton Hospital

Moncton, New Brunswick, Canada

E1C 6Z8 

Contact: Ian Chute, MSc    

Principal Investigator: Mahmoud Abdelsalam, MD          



The Ottawa Hospital

Ottawa, Ontario, Canada

K1H 8L6 

Contact: Lenah Mukhtar 

Principal Investigator: John Hilton, MD


Odette Cancer Centre - Sunnybrook Hospital

Toronto, Ontario, Canada

M4N 3M5 

Contact: Mark Gichuru    

Principal Investigator: Helen MacKay, MD



Centre hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

H2X 0A9 

Contact: Renée Bernatchez    

Principal Investigator: Fred Saad, MD


Jewish General Hospital

Montreal, Quebec

H3T 1E2   

Contact: Caterina Marcangione    

Principal Investigator: Mark Basik, MD


Centre hospitalier universitaire de Québec - Université Laval

Québec, Quebec, Canada

G1S 4L8

Contact: Jean-Charles Hogue, PhD    

Principal Investigator: Louise Provencher, MD


Centre hospitalier universitaire de Sherbrooke

Sherbrooke, Quebec, Canada

J1G 2E8 

Contact: Noémie Poirier    

Contact: Suzanne Maltais  

Principal Investigator: Julie Carrier, MD          

CIUSSS MCQ (Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie-et-du-Centre-du-Québec)

Centre Hospitalier Affilié Universitaire Régional

Trois-Rivières, Quebec, Canada

G8Z 3R9

Hôtel-Dieu d'Arthabaska

Victoriaville, Quebec, Canada

G6P 6N2

Contact: Marie-Eve Caron 

Principal Investigator: François Vincent, MD


1001 Décarie Blvd

Montreal, Quebec

H4A 3J1

Contact: Jessica Mancuso,

PI: Dr Jonathan Spicer,

5450 Chemin de la Côte-des-Neiges

Suite 522

Montréal, Qc

H3T 1Y6


  • White LinkedIn Icon
Send Us a Message

© 2020 by Exactis Innovation